March 23, 2021 09:46 AM EDTUpdated 11:18 AM

'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials

Nicole DeFeudis

Editor

Moderna emerged as an early leader in the race for a vaccine to stop Covid-19 in its tracks. The Cambridge, Massachusetts-based biotech bounded through development …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

'Part of re­cov­ery is aware­ness': Pan­dem­ic casts harsh spot­light on in­dus­try-wide lack of di­ver­si­ty in clin­i­cal tri­als

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials